North America Botulinum Toxin Market Size, Share & Industry Trends Analysis Report By Product, By Application (Therapeutic and Aesthetic), By End User (Hospitals, Dermatology Clinics and Spas & Cosmetic Centers, By Country and Growth Forecast, 2022 - 2028
Description
North America Botulinum Toxin Market Size, Share & Industry Trends Analysis Report By Product, By Application (Therapeutic and Aesthetic), By End User (Hospitals, Dermatology Clinics and Spas & Cosmetic Centers, By Country and Growth Forecast, 2022 - 2028
The North America Botulinum Toxin Market would witness market growth of 10.3% CAGR during the forecast period (2022-2028).
Glabellar lines, crow's feet, or forehead lines are among the age-related diseases that are treated with botulinum toxin. As a result, adults over 40 are more susceptible to these aging symptoms. As a result, among those between the ages of 40 and 55, botulinum toxin procedures are becoming more and more popular, supporting business growth.
Botulinum toxin administered intramuscularly causes muscle paralysis at the neuromuscular junction by inhibiting the release of acetylcholine by presynaptic motor neurons. The autonomic ganglia, neuromuscular junction, postganglionic parasympathetic nerve terminals, and postganglionic sympathetic nerve ends that release acetylcholine are the four places in the body where botulinum toxins activate. The cholinergic neurons’ presynaptic surface has high-affinity receptors that the toxin's heavy (H) chain preferentially and irreversibly attach to. The toxin-receptor complex is then taken up into the cell through endocytosis. In order for the poison to escape into the cytoplasm, the disulfide connection holding the two chains together is broken.
The utilization of botulinum toxin is increasing in the region in recent years. Not all headaches are bad with migraine. Compared to other headache illnesses, it is a disabling neurological disease with unique symptoms and a unique strategy for therapy. According to the American Migraine Foundation, approximately 39 million Americans suffer from migraines, however, the true figure is likely greater because many sufferers do not receive a proper diagnosis or treatment.
The US market dominated the North America Botulinum Toxin Market by Country in 2021, and would continue to be a dominant market till 2028; thereby, achieving a market value of $2,774.1 Million by 2028.The Canada market is poised to grow at a CAGR of 12.8% during (2022 - 2028). Additionally, The Mexico market would witness a CAGR of 11.8% during (2022 - 2028).
Based on Product, the market is segmented into Type A and Type B. Based on Application, the market is segmented into Therapeutic and Aesthetic. Based on End User, the market is segmented into Hospitals, Dermatology Clinics and Spas & Cosmetic Centers. Based on countries, the market is segmented into U.S., Mexico, Canada, and Rest of North America.
The market research report covers the analysis of key stake holders of the market. Key companies profiled in the report include Evolus, Inc. (Alphaeon Corporation), Merz Pharma GmbH & Co. KGaA, AbbVie, Inc., Ipsen Pharma, Galderma S.A., USWM, LLC, and Metabiologics, Inc. (Object Pharma).
Scope of the Study
Market Segments covered in the Report:
By Product
The North America Botulinum Toxin Market would witness market growth of 10.3% CAGR during the forecast period (2022-2028).
Glabellar lines, crow's feet, or forehead lines are among the age-related diseases that are treated with botulinum toxin. As a result, adults over 40 are more susceptible to these aging symptoms. As a result, among those between the ages of 40 and 55, botulinum toxin procedures are becoming more and more popular, supporting business growth.
Botulinum toxin administered intramuscularly causes muscle paralysis at the neuromuscular junction by inhibiting the release of acetylcholine by presynaptic motor neurons. The autonomic ganglia, neuromuscular junction, postganglionic parasympathetic nerve terminals, and postganglionic sympathetic nerve ends that release acetylcholine are the four places in the body where botulinum toxins activate. The cholinergic neurons’ presynaptic surface has high-affinity receptors that the toxin's heavy (H) chain preferentially and irreversibly attach to. The toxin-receptor complex is then taken up into the cell through endocytosis. In order for the poison to escape into the cytoplasm, the disulfide connection holding the two chains together is broken.
The utilization of botulinum toxin is increasing in the region in recent years. Not all headaches are bad with migraine. Compared to other headache illnesses, it is a disabling neurological disease with unique symptoms and a unique strategy for therapy. According to the American Migraine Foundation, approximately 39 million Americans suffer from migraines, however, the true figure is likely greater because many sufferers do not receive a proper diagnosis or treatment.
The US market dominated the North America Botulinum Toxin Market by Country in 2021, and would continue to be a dominant market till 2028; thereby, achieving a market value of $2,774.1 Million by 2028.The Canada market is poised to grow at a CAGR of 12.8% during (2022 - 2028). Additionally, The Mexico market would witness a CAGR of 11.8% during (2022 - 2028).
Based on Product, the market is segmented into Type A and Type B. Based on Application, the market is segmented into Therapeutic and Aesthetic. Based on End User, the market is segmented into Hospitals, Dermatology Clinics and Spas & Cosmetic Centers. Based on countries, the market is segmented into U.S., Mexico, Canada, and Rest of North America.
The market research report covers the analysis of key stake holders of the market. Key companies profiled in the report include Evolus, Inc. (Alphaeon Corporation), Merz Pharma GmbH & Co. KGaA, AbbVie, Inc., Ipsen Pharma, Galderma S.A., USWM, LLC, and Metabiologics, Inc. (Object Pharma).
Scope of the Study
Market Segments covered in the Report:
By Product
- Type A
- Type B
- Therapeutic
- Aesthetic
- Hospitals
- Dermatology Clinics
- Spas & Cosmetic Centers
- US
- Canada
- Mexico
- Rest of North America
- Evolus, Inc. (Alphaeon Corporation)
- Merz Pharma GmbH & Co. KGaA
- AbbVie, Inc.
- Ipsen Pharma
- Galderma S.A.
- USWM, LLC
- Metabiologics, Inc. (Object Pharma)
- Exhaustive coverage
- Highest number of market tables and figures
- Subscription based model available
- Guaranteed best price
- Assured post sales research support with 10% customization free
Table of Contents
56 Pages
- Chapter 1. Market Scope & Methodology
- 1.1 Market Definition
- 1.2 Objectives
- 1.3 Market Scope
- 1.4 Segmentation
- 1.4.1 North America Botulinum Toxin Market, by Product
- 1.4.2 North America Botulinum Toxin Market, by Application
- 1.4.3 North America Botulinum Toxin Market, by End User
- 1.4.4 North America Botulinum Toxin Market, by Country
- 1.5 Methodology for the research
- Chapter 2. Market Overview
- 2.1 Introduction
- 2.1.1 Overview
- 2.1.1.1 Market composition and scenario
- 2.2 Key Factors Impacting the Market
- 2.2.1 Market Drivers
- 2.2.2 Market Restraints
- Chapter 3. Strategies deployed in Botulinum Toxin Market
- Chapter 4. North America Botulinum Toxin Market by Product
- 4.1 North America Type A Market by Country
- 4.2 North America Type B Market by Country
- Chapter 5. North America Botulinum Toxin Market by Application
- 5.1 North America Therapeutic Market by Country
- 5.2 North America Aesthetic Market by Country
- Chapter 6. North America Botulinum Toxin Market by End User
- 6.1 North America Hospitals Market by Country
- 6.2 North America Dermatology Clinics Market by Country
- 6.3 North America Spas & Cosmetic Centers Market by Country
- Chapter 7. North America Botulinum Toxin Market by Country
- 7.1 US Botulinum Toxin Market
- 7.1.1 US Botulinum Toxin Market by Product
- 7.1.2 US Botulinum Toxin Market by Application
- 7.1.3 US Botulinum Toxin Market by End User
- 7.2 Canada Botulinum Toxin Market
- 7.2.1 Canada Botulinum Toxin Market by Product
- 7.2.2 Canada Botulinum Toxin Market by Application
- 7.2.3 Canada Botulinum Toxin Market by End User
- 7.3 Mexico Botulinum Toxin Market
- 7.3.1 Mexico Botulinum Toxin Market by Product
- 7.3.2 Mexico Botulinum Toxin Market by Application
- 7.3.3 Mexico Botulinum Toxin Market by End User
- 7.4 Rest of North America Botulinum Toxin Market
- 7.4.1 Rest of North America Botulinum Toxin Market by Product
- 7.4.2 Rest of North America Botulinum Toxin Market by Application
- 7.4.3 Rest of North America Botulinum Toxin Market by End User
- Chapter 8. Company Profiles
- 8.1 Evolus, Inc. (Alphaeon Corporation)
- 8.1.1 Company Overview
- 8.1.2 Financial Analysis
- 8.1.3 Research & Development Expenses
- 8.1.4 Recent strategies and developments:
- 8.1.4.1 Approvals and Trials:
- 8.2 Merz Pharma GmbH & Co. KGaA
- 8.2.1 Company Overview
- 8.2.2 Recent strategies and developments:
- 8.2.2.1 Approvals and Trials:
- 8.3 AbbVie, Inc.
- 8.3.1 Company Overview
- 8.3.2 Financial Analysis
- 8.3.3 Regional Analysis
- 8.3.4 Research & Development Expense
- 8.3.5 Recent strategies and developments:
- 8.3.5.1 Acquisition and Mergers:
- 8.3.5.2 Approvals and Trials:
- 8.4 Ipsen Pharma
- 8.4.1 Company Overview
- 8.4.2 Financial Analysis
- 8.4.3 Segmental and Regional Analysis
- 8.4.4 Research & Development Expenses
- 8.4.5 Recent strategies and developments:
- 8.4.5.1 Approvals and Trials:
- 8.5 Galderma S.A.
- 8.5.1 Company Overview
- 8.5.2 Recent strategies and developments:
- 8.5.2.1 Geographical Expansions:
- 8.6 USWM, LLC
- 8.6.1 Company Overview
- 8.7 Metabiologics, Inc. (Object Pharma, Inc.)
- 8.7.1 Company Overview
Pricing
Currency Rates
Questions or Comments?
Our team has the ability to search within reports to verify it suits your needs. We can also help maximize your budget by finding sections of reports you can purchase.
